Please join PPMD and Avidity Biosciences for a community webinar on Friday, March 28, 2025 at 2:00 PM ET. Avidity will share topline data from their EXPLORE44® clinical trial, which is assessing the safety and efficacy of the investigational therapy delpacibart zotadirsen (formerly AOC 1044, abbreviated as del-zota) in people living with Duchenne mutations amenable to exon 44 skipping.

Please submit questions in advance here.

Register for the webinar here.